Alpha Tau Medical (DRTS) Stock Forecast, Price Target & Predictions
DRTS Stock Forecast
Alpha Tau Medical stock forecast is as follows: an average price target of $7.00 (represents a 212.50% upside from DRTS’s last price of $2.24) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
DRTS Price Target
The average price target for Alpha Tau Medical (DRTS) is $7.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $7.00 to $7.00. This represents a potential 212.50% upside from DRTS's last price of $2.24.
DRTS Analyst Ratings
According to 2 Wall Street analysts, Alpha Tau Medical's rating consensus is 'Buy'. The analyst rating breakdown for DRTS stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Alpha Tau Medical Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 21, 2024 | Jason Bednar | Piper Sandler | $7.00 | $2.91 | 140.55% | 212.50% |
| Nov 23, 2022 | - | Piper Sandler | $12.00 | $3.75 | 220.00% | 435.71% |
The latest Alpha Tau Medical stock forecast, released on May 21, 2024 by Jason Bednar from Piper Sandler, set a price target of $7.00, which represents a 140.55% increase from the stock price at the time of the forecast ($2.91), and a 212.50% increase from DRTS last price ($2.24).
Alpha Tau Medical Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $7.00 |
| Last Closing Price | $2.24 | $2.24 | $2.24 |
| Upside/Downside | -100.00% | -100.00% | 212.50% |
In the current month, the average price target of Alpha Tau Medical stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Alpha Tau Medical's last price of $2.24. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 11, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 21, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 15, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| May 21, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Nov 23, 2022 | Piper Sandler | Overweight | Overweight | Hold |
Alpha Tau Medical's last stock rating was published by H.C. Wainwright on Oct 11, 2024. The company gave DRTS a "Buy" rating, the same as its previous rate.
Alpha Tau Medical Financial Forecast
Alpha Tau Medical Revenue Forecast
| Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $20.68M | $14.48M | $5.80M | $5.60M | $3.70M | $2.20M | $533.33K | $466.67K | $200.00K | $100.00K | $150.00K | $62.50K | $30.00K |
| High Forecast | $20.68M | $14.48M | $5.80M | $5.60M | $3.70M | $2.20M | $533.33K | $466.67K | $200.00K | $100.00K | $150.00K | $62.50K | $30.00K |
| Low Forecast | $20.68M | $14.48M | $5.80M | $5.60M | $3.70M | $2.20M | $533.33K | $466.67K | $200.00K | $100.00K | $150.00K | $62.50K | $30.00K |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alpha Tau Medical's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. DRTS's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Alpha Tau Medical EBITDA Forecast
| Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
undefined analysts predict DRTS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Alpha Tau Medical's previous annual EBITDA (undefined) of $NaN.
Alpha Tau Medical Net Income Forecast
| Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-9.08M | $-12.58M | $-9.08M | $-8.38M | $-8.38M | $-8.38M | $-9.78M | $-9.32M | $-8.38M | $-8.41M | $-8.97M | $-8.41M | $-8.04M |
| High Forecast | $-9.08M | $-12.58M | $-9.08M | $-8.38M | $-8.38M | $-8.38M | $-9.78M | $-9.32M | $-8.38M | $-8.41M | $-8.97M | $-7.76M | $-8.04M |
| Low Forecast | $-9.08M | $-12.58M | $-9.08M | $-8.38M | $-8.38M | $-8.38M | $-9.78M | $-9.32M | $-8.38M | $-8.41M | $-8.97M | $-9.05M | $-8.04M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alpha Tau Medical's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. DRTS's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Alpha Tau Medical SG&A Forecast
| Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
Alpha Tau Medical's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to DRTS last annual SG&A of $NaN (undefined).
Alpha Tau Medical EPS Forecast
| Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-0.13 | $-0.18 | $-0.13 | $-0.12 | $-0.12 | $-0.12 | $-0.14 | $-0.13 | $-0.12 | $-0.12 | $-0.13 | $-0.12 | $-0.12 |
| High Forecast | $-0.13 | $-0.18 | $-0.13 | $-0.12 | $-0.12 | $-0.12 | $-0.14 | $-0.13 | $-0.12 | $-0.12 | $-0.13 | $-0.11 | $-0.12 |
| Low Forecast | $-0.13 | $-0.18 | $-0.13 | $-0.12 | $-0.12 | $-0.12 | $-0.14 | $-0.13 | $-0.12 | $-0.12 | $-0.13 | $-0.13 | $-0.12 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Alpha Tau Medical's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to DRTS previous annual EPS of $NaN (undefined).
Alpha Tau Medical Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| MOLN | Molecular Partners | $6.06 | $29.00 | 378.55% | Buy |
| INZY | Inozyme Pharma | $4.42 | $14.67 | 231.90% | Buy |
| DRTS | Alpha Tau Medical | $2.24 | $7.00 | 212.50% | Buy |
| ELYM | Eliem Therapeutics | $5.11 | $13.00 | 154.40% | Buy |
| GNFT | Genfit | $5.76 | $13.00 | 125.69% | Buy |
| OCUL | Ocular Therapeutix | $10.27 | $17.50 | 70.40% | Buy |
| CYT | Cyteir Therapeutics | $3.02 | $2.00 | -33.77% | Sell |
DRTS Forecast FAQ
Is Alpha Tau Medical a good buy?
Yes, according to 2 Wall Street analysts, Alpha Tau Medical (DRTS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of DRTS's total ratings.
What is DRTS's price target?
Alpha Tau Medical (DRTS) average price target is $7 with a range of $7 to $7, implying a 212.50% from its last price of $2.24. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Alpha Tau Medical stock go up soon?
According to Wall Street analysts' prediction for DRTS stock, the company can go up by 212.50% (from the last price of $2.24 to the average price target of $7), up by 212.50% based on the highest stock price target, and up by 212.50% based on the lowest stock price target.
Can Alpha Tau Medical stock reach $3?
DRTS's average twelve months analyst stock price target of $7 supports the claim that Alpha Tau Medical can reach $3 in the near future.
What are Alpha Tau Medical's analysts' financial forecasts?
Alpha Tau Medical's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.3M (high $1.3M, low $1.3M), average EBITDA is $0 (high $0, low $0), average net income is $-35.887M (high $-35.887M, low $-35.887M), average SG&A $0 (high $0, low $0), and average EPS is $-0.514 (high $-0.514, low $-0.514). DRTS's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $17.3M (high $17.3M, low $17.3M), average EBITDA is $0 (high $0, low $0), average net income is $-34.237M (high $-34.237M, low $-34.237M), average SG&A $0 (high $0, low $0), and average EPS is $-0.49 (high $-0.49, low $-0.49).